(1->4)-beta-D-glucan multiple interactions ISO RGD:732479 6480464 [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of ERO1L mRNA CTD PMID:36331819 1,1-dichloroethene increases expression ISO RGD:732479 6480464 vinylidene chloride results in increased expression of ERO1A mRNA CTD PMID:26682919 1,2-dimethylhydrazine decreases expression ISO RGD:732479 6480464 1, 2-Dimethylhydrazine results in decreased expression of ERO1L mRNA CTD PMID:22206623 17beta-hydroxy-5alpha-androstan-3-one increases expression ISO RGD:1317870 6480464 Dihydrotestosterone results in increased expression of ERO1A mRNA CTD PMID:29581250 1H-pyrazole increases expression ISO RGD:732479 6480464 pyrazole results in increased expression of ERO1A mRNA CTD PMID:17945193 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of ERO1A mRNA CTD PMID:25529477 , PMID:33387578 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:732479 6480464 [TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ERO1A mRNA CTD PMID:25975270 2,6-dinitrotoluene affects expression EXP 6480464 2, 6-dinitrotoluene affects the expression of ERO1A mRNA CTD PMID:21346803 2-hydroxypropanoic acid decreases expression ISO RGD:1317870 6480464 Lactic Acid results in decreased expression of ERO1A mRNA CTD PMID:30851411 3,3',4,4',5-pentachlorobiphenyl increases expression EXP 6480464 3 more ... CTD PMID:23196670 3-chloropropane-1,2-diol decreases expression EXP 6480464 alpha-Chlorohydrin results in decreased expression of ERO1A protein CTD PMID:26072098 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO RGD:1317870 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of ERO1A mRNA CTD PMID:28628672 4,4'-sulfonyldiphenol multiple interactions ISO RGD:1317870 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of ERO1A mRNA CTD PMID:28628672 4,4'-sulfonyldiphenol multiple interactions EXP 6480464 [bisphenol A co-treated with bisphenol F co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of ERO1A mRNA CTD PMID:36041667 adefovir pivoxil increases expression ISO RGD:1317870 6480464 adefovir dipivoxil results in increased expression of ERO1A mRNA CTD PMID:25596134 aflatoxin B1 decreases expression ISO RGD:732479 6480464 Aflatoxin B1 results in decreased expression of ERO1A mRNA CTD PMID:19770486 aldehydo-D-glucose decreases expression ISO RGD:732479 6480464 Glucose results in decreased expression of ERO1A mRNA CTD PMID:17178593 aldehydo-D-glucose multiple interactions EXP 6480464 Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of ERO1A protein], Metformin inhibits the reaction [Glucose results in increased expression of ERO1A protein] CTD PMID:34801538 aldehydo-D-glucose increases expression EXP 6480464 Glucose results in increased expression of ERO1A protein CTD PMID:34801538 all-trans-retinoic acid increases expression ISO RGD:1317870 6480464 Tretinoin results in increased expression of ERO1A mRNA CTD PMID:33167477 ammonium chloride affects expression EXP 6480464 Ammonium Chloride affects the expression of ERO1A mRNA CTD PMID:16483693 amphetamine increases expression EXP 6480464 Amphetamine results in increased expression of ERO1A mRNA CTD PMID:30779732 antimycin A increases expression ISO RGD:732479 6480464 Antimycin A results in increased expression of ERO1A mRNA CTD PMID:19304788 aristolochic acid A decreases expression ISO RGD:1317870 6480464 aristolochic acid I results in decreased expression of ERO1A mRNA CTD PMID:33212167 Aroclor 1254 decreases expression ISO RGD:732479 6480464 Chlorodiphenyl (54% Chlorine) results in decreased expression of ERO1A mRNA CTD PMID:23650126 arsane multiple interactions ISO RGD:1317870 6480464 [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of ERO1A mRNA CTD PMID:32525701 arsenic atom multiple interactions ISO RGD:1317870 6480464 [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of ERO1A mRNA CTD PMID:32525701 arsenite(3-) increases expression ISO RGD:732479 6480464 arsenite results in increased expression of ERO1A protein CTD PMID:35964836 arsenite(3-) multiple interactions ISO RGD:1317870 6480464 2-(4-chlorophenoxy)-N-(4-(2-(4-chlorophenoxy)acetamido)cyclohexyl)acetamide inhibits the reaction [arsenite results in increased expression of ERO1A protein] CTD PMID:35964836 arsenite(3-) affects response to substance ISO RGD:732479 6480464 ERO1A protein affects the susceptibility to arsenite CTD PMID:35964836 arsenite(3-) increases expression ISO RGD:1317870 6480464 arsenite results in increased expression of ERO1A protein CTD PMID:35964836 arsenite(3-) multiple interactions ISO RGD:732479 6480464 2-(4-chlorophenoxy)-N-(4-(2-(4-chlorophenoxy)acetamido)cyclohexyl)acetamide inhibits the reaction [arsenite results in increased expression of ERO1A protein], ERO1A protein affects the reaction [arsenite results in increased activity of CASP3 protein] CTD PMID:35964836 benzene-1,2,4-triol increases expression ISO RGD:1317870 6480464 hydroxyhydroquinone results in increased expression of ERO1A mRNA CTD PMID:17572062 benzo[a]pyrene diol epoxide I affects expression ISO RGD:1317870 6480464 7 more ... CTD PMID:20382639 bis(2-ethylhexyl) phthalate decreases expression ISO RGD:1317870 6480464 Diethylhexyl Phthalate results in decreased expression of ERO1A protein CTD PMID:31163220 bis(2-ethylhexyl) phthalate affects expression ISO RGD:732479 6480464 Diethylhexyl Phthalate affects the expression of ERO1A mRNA CTD PMID:21318169 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of ERO1A mRNA CTD PMID:25181051 bisphenol A multiple interactions EXP 6480464 [bisphenol A co-treated with bisphenol F co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of ERO1A mRNA CTD PMID:36041667 bisphenol A decreases expression ISO RGD:1317870 6480464 bisphenol A results in decreased expression of ERO1A protein CTD PMID:31675489 bisphenol A affects expression ISO RGD:1317870 6480464 bisphenol A affects the expression of ERO1A mRNA CTD PMID:30903817 bisphenol F multiple interactions EXP 6480464 [bisphenol A co-treated with bisphenol F co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of ERO1A mRNA CTD PMID:36041667 cadmium dichloride affects expression ISO RGD:1317870 6480464 Cadmium Chloride affects the expression of ERO1A mRNA CTD PMID:25596134 calcitriol increases expression ISO RGD:1317870 6480464 Calcitriol results in increased expression of ERO1A mRNA CTD PMID:21592394 calcitriol multiple interactions ISO RGD:1317870 6480464 [Testosterone co-treated with Calcitriol] results in increased expression of ERO1A mRNA CTD PMID:21592394 calyculin a increases expression ISO RGD:732479 6480464 calyculin A results in increased expression of ERO1A mRNA CTD PMID:25270620 carbon monoxide increases expression EXP 6480464 Carbon Monoxide results in increased expression of ERO1A mRNA CTD PMID:12752442 chloroacetaldehyde increases expression ISO RGD:1317870 6480464 chloroacetaldehyde results in increased expression of ERO1A mRNA CTD PMID:25596134 chlorogenic acid multiple interactions EXP 6480464 Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of ERO1A protein] CTD PMID:34801538 chlorpromazine increases expression EXP 6480464 Chlorpromazine results in increased expression of ERO1A mRNA CTD PMID:25596134 chromium(6+) affects expression ISO RGD:732479 6480464 chromium hexavalent ion affects the expression of ERO1A mRNA CTD PMID:28472532 cidofovir anhydrous increases expression ISO RGD:1317870 6480464 Cidofovir results in increased expression of ERO1A mRNA CTD PMID:25596134 cobalt atom increases expression EXP 6480464 Cobalt results in increased expression of ERO1A mRNA CTD PMID:12752442 cobalt dichloride increases expression EXP 6480464 cobaltous chloride results in increased expression of ERO1A mRNA CTD PMID:24386269 cobalt dichloride increases expression ISO RGD:1317870 6480464 cobaltous chloride results in increased expression of ERO1A mRNA CTD PMID:19320972 , PMID:19376846 cyclosporin A decreases expression ISO RGD:1317870 6480464 Cyclosporine results in decreased expression of ERO1A mRNA CTD PMID:21163907 cyclosporin A increases expression ISO RGD:732479 6480464 Cyclosporine results in increased expression of ERO1A mRNA CTD PMID:23830897 , PMID:23958496 cyclosporin A increases expression ISO RGD:1317870 6480464 Cyclosporine results in increased expression of ERO1A mRNA CTD PMID:20106945 more ... D-glucose decreases expression ISO RGD:732479 6480464 Glucose results in decreased expression of ERO1A mRNA CTD PMID:17178593 D-glucose increases expression EXP 6480464 Glucose results in increased expression of ERO1A protein CTD PMID:34801538 D-glucose multiple interactions EXP 6480464 Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of ERO1A protein], Metformin inhibits the reaction [Glucose results in increased expression of ERO1A protein] CTD PMID:34801538 decabromodiphenyl ether increases expression EXP 6480464 decabromobiphenyl ether results in increased expression of ERO1A mRNA CTD PMID:23640034 decabromodiphenyl ether decreases expression ISO RGD:1317870 6480464 decabromobiphenyl ether results in decreased expression of ERO1A protein CTD PMID:31675489 deguelin increases expression ISO RGD:1317870 6480464 deguelin results in increased expression of ERO1A mRNA CTD PMID:33512557 desferrioxamine B increases expression ISO RGD:1317870 6480464 Deferoxamine results in increased expression of ERO1A mRNA CTD PMID:12752442 desferrioxamine B increases expression ISO RGD:732479 6480464 Deferoxamine results in increased expression of ERO1A mRNA CTD PMID:12752442 desferrioxamine B increases expression EXP 6480464 Deferoxamine results in increased expression of ERO1A mRNA CTD PMID:12752442 dexamethasone multiple interactions ISO RGD:1317870 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of ERO1A mRNA CTD PMID:28628672 dibutyl phthalate decreases expression EXP 6480464 Dibutyl Phthalate results in decreased expression of ERO1A mRNA CTD PMID:21266533 diclofenac increases expression ISO RGD:732479 6480464 Diclofenac results in increased expression of ERO1A mRNA CTD PMID:26934552 dioxygen increases expression EXP 6480464 Oxygen deficiency results in increased expression of ERO1A mRNA, Oxygen deficiency results in increased expression of ERO1A protein CTD PMID:12752442 dioxygen multiple interactions EXP 6480464 [Oxygen deficiency co-treated with Blood Glucose deficiency co-treated with Particulate Matter] results in increased expression of ERO1A mRNA CTD PMID:33729688 dioxygen increases expression ISO RGD:732479 6480464 Oxygen deficiency results in increased expression of ERO1A, Oxygen deficiency results in increased expression of ERO1A mRNA CTD PMID:12752442 , PMID:20880076 dioxygen increases expression ISO RGD:1317870 6480464 Oxygen deficiency results in increased expression of ERO1A, Oxygen deficiency results in increased expression of ERO1A mRNA CTD PMID:12752442 more ... dorsomorphin multiple interactions ISO RGD:1317870 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERO1A mRNA CTD PMID:27188386 doxorubicin decreases expression ISO RGD:1317870 6480464 Doxorubicin results in decreased expression of ERO1A mRNA CTD PMID:29803840 endosulfan increases expression EXP 6480464 Endosulfan results in increased expression of ERO1A mRNA CTD PMID:31464424 enzyme inhibitor multiple interactions ISO RGD:1317870 6480464 [Enzyme Inhibitors results in decreased activity of OGA protein] which results in increased O-linked glycosylation of ERO1A protein CTD PMID:23301498 ethanol affects splicing ISO RGD:732479 6480464 Ethanol affects the splicing of ERO1A mRNA CTD PMID:30319688 ethanol multiple interactions ISO RGD:1317870 6480464 [Ethanol co-treated with Folic Acid] results in increased expression of ERO1A mRNA CTD PMID:23378141 ethyl methanesulfonate decreases expression ISO RGD:1317870 6480464 Ethyl Methanesulfonate results in decreased expression of ERO1A mRNA CTD PMID:23649840 fenofibrate increases expression EXP 6480464 Fenofibrate results in increased expression of ERO1A mRNA CTD PMID:25596134 fenpyroximate increases expression ISO RGD:1317870 6480464 fenpyroximate results in increased expression of ERO1A mRNA CTD PMID:33512557 folic acid multiple interactions ISO RGD:1317870 6480464 [Ethanol co-treated with Folic Acid] results in increased expression of ERO1A mRNA CTD PMID:23378141 formaldehyde decreases expression ISO RGD:1317870 6480464 Formaldehyde results in decreased expression of ERO1A mRNA CTD PMID:23649840 gentamycin increases expression EXP 6480464 Gentamicins results in increased expression of ERO1A mRNA CTD PMID:22061828 glucose decreases expression ISO RGD:732479 6480464 Glucose results in decreased expression of ERO1A mRNA CTD PMID:17178593 glucose multiple interactions EXP 6480464 Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of ERO1A protein], Metformin inhibits the reaction [Glucose results in increased expression of ERO1A protein] CTD PMID:34801538 glucose increases expression EXP 6480464 Glucose results in increased expression of ERO1A protein CTD PMID:34801538 gold atom increases expression ISO RGD:1317870 6480464 Gold results in increased expression of ERO1A mRNA CTD PMID:29705079 gold(0) increases expression ISO RGD:1317870 6480464 Gold results in increased expression of ERO1A mRNA CTD PMID:29705079 homocysteine decreases expression ISO RGD:1317870 6480464 Homocysteine results in decreased expression of ERO1A protein CTD PMID:22964297 ifosfamide increases expression ISO RGD:1317870 6480464 Ifosfamide results in increased expression of ERO1A mRNA CTD PMID:25596134 indometacin multiple interactions ISO RGD:1317870 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of ERO1A mRNA CTD PMID:28628672 ivermectin decreases expression ISO RGD:1317870 6480464 Ivermectin results in decreased expression of ERO1A protein CTD PMID:32959892 lead(0) affects expression ISO RGD:1317870 6480464 Lead affects the expression of ERO1A mRNA CTD PMID:28903495 lead(2+) affects expression ISO RGD:1317870 6480464 Lead affects the expression of ERO1A mRNA CTD PMID:28903495 lipopolysaccharide increases expression ISO RGD:732479 6480464 Lipopolysaccharides results in increased expression of ERO1A mRNA CTD PMID:27339419 metformin multiple interactions EXP 6480464 Metformin inhibits the reaction [Glucose results in increased expression of ERO1A protein] CTD PMID:34801538 methyl methanesulfonate decreases expression ISO RGD:1317870 6480464 Methyl Methanesulfonate results in decreased expression of ERO1A mRNA CTD PMID:23649840 nickel dichloride affects expression EXP 6480464 nickel chloride affects the expression of ERO1A mRNA CTD PMID:22110744 nickel dichloride multiple interactions ISO RGD:732479 6480464 HIF1A affects the reaction [nickel chloride results in increased expression of ERO1A mRNA] CTD PMID:12729255 nickel dichloride increases expression ISO RGD:732479 6480464 nickel chloride results in increased expression of ERO1A mRNA CTD PMID:12729255 nickel subsulfide affects expression ISO RGD:732479 6480464 nickel subsulfide affects the expression of ERO1A mRNA CTD PMID:12729255 ochratoxin A decreases expression ISO RGD:1317870 6480464 ochratoxin A results in decreased expression of ERO1A mRNA CTD PMID:30559759 okadaic acid increases expression EXP 6480464 Okadaic Acid results in increased expression of ERO1A protein CTD PMID:26732598 paracetamol decreases expression ISO RGD:1317870 6480464 Acetaminophen results in decreased expression of ERO1A mRNA CTD PMID:21420995 paracetamol affects expression ISO RGD:732479 6480464 Acetaminophen affects the expression of ERO1A mRNA CTD PMID:17562736 perfluorooctane-1-sulfonic acid multiple interactions ISO RGD:732479 6480464 [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of ERO1L mRNA CTD PMID:36331819 picoxystrobin increases expression ISO RGD:1317870 6480464 picoxystrobin results in increased expression of ERO1A mRNA CTD PMID:33512557 propiconazole increases expression ISO RGD:732479 6480464 propiconazole results in increased expression of ERO1A mRNA CTD PMID:21278054 rac-lactic acid decreases expression ISO RGD:1317870 6480464 Lactic Acid results in decreased expression of ERO1A mRNA CTD PMID:30851411 resveratrol decreases expression EXP 6480464 resveratrol results in decreased expression of ERO1A mRNA CTD PMID:19228061 resveratrol multiple interactions ISO RGD:1317870 6480464 [Plant Extracts co-treated with Resveratrol] results in increased expression of ERO1A mRNA CTD PMID:23557933 resveratrol multiple interactions ISO RGD:732479 6480464 ERO1A protein inhibits the reaction [Resveratrol results in decreased secretion of ADIPOQ protein] CTD PMID:17452443 rotenone increases expression ISO RGD:1317870 6480464 Rotenone results in increased expression of ERO1A mRNA CTD PMID:33512557 rotenone increases expression ISO RGD:732479 6480464 Rotenone results in increased expression of ERO1A mRNA CTD PMID:19304788 SB 431542 multiple interactions ISO RGD:1317870 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERO1A mRNA CTD PMID:27188386 serpentine asbestos increases expression ISO RGD:1317870 6480464 Asbestos, Serpentine results in increased expression of ERO1A mRNA CTD PMID:29523930 silver atom increases expression ISO RGD:732479 6480464 Silver results in increased expression of ERO1A mRNA CTD PMID:27131904 silver(0) increases expression ISO RGD:732479 6480464 Silver results in increased expression of ERO1A mRNA CTD PMID:27131904 sirolimus multiple interactions EXP 6480464 Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased expression of ERO1A mRNA] CTD PMID:19420259 sodium arsenate multiple interactions ISO RGD:1317870 6480464 [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of ERO1A mRNA CTD PMID:32525701 sodium arsenite decreases expression EXP 6480464 sodium arsenite results in decreased expression of ERO1A protein CTD PMID:29459688 sodium fluoride decreases expression ISO RGD:732479 6480464 Sodium Fluoride results in decreased expression of ERO1A protein CTD PMID:28918527 sotorasib multiple interactions ISO RGD:1317870 6480464 [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ERO1A mRNA CTD PMID:36139627 succimer multiple interactions ISO RGD:732479 6480464 [Succimer co-treated with Magnetite Nanoparticles] results in increased expression of ERO1A mRNA CTD PMID:26378955 sunitinib increases expression ISO RGD:1317870 6480464 Sunitinib results in increased expression of ERO1A mRNA CTD PMID:31533062 T-2 toxin decreases expression EXP 6480464 T-2 Toxin results in decreased expression of ERO1A mRNA CTD PMID:26141394 tacrolimus hydrate increases expression ISO RGD:732479 6480464 Tacrolimus results in increased expression of ERO1A mRNA CTD PMID:23958496 tebufenpyrad increases expression ISO RGD:1317870 6480464 4-chloro-N-((4-(1, 1-dimethylethyl)phenyl)methyl)-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide results in increased expression of ERO1A mRNA CTD PMID:33512557 temozolomide decreases expression ISO RGD:1317870 6480464 Temozolomide results in decreased expression of ERO1A mRNA CTD PMID:31758290 Tesaglitazar increases expression EXP 6480464 tesaglitazar results in increased expression of ERO1A mRNA CTD PMID:21515302 testosterone increases expression ISO RGD:1317870 6480464 Testosterone results in increased expression of ERO1A mRNA CTD PMID:21592394 testosterone multiple interactions ISO RGD:1317870 6480464 [Testosterone co-treated with Calcitriol] results in increased expression of ERO1A mRNA CTD PMID:21592394 tetrachloromethane increases expression ISO RGD:732479 6480464 Carbon Tetrachloride results in increased expression of ERO1A mRNA CTD PMID:27339419 , PMID:31919559 thapsigargin increases expression EXP 6480464 Thapsigargin results in increased expression of ERO1A protein CTD PMID:28315715 thapsigargin multiple interactions ISO RGD:732479 6480464 2-(4-chlorophenoxy)-N-(4-(2-(4-chlorophenoxy)acetamido)cyclohexyl)acetamide inhibits the reaction [Thapsigargin results in increased expression of ERO1A protein] CTD PMID:35964836 thapsigargin multiple interactions ISO RGD:1317870 6480464 2-(4-chlorophenoxy)-N-(4-(2-(4-chlorophenoxy)acetamido)cyclohexyl)acetamide inhibits the reaction [Thapsigargin results in increased expression of ERO1A protein] CTD PMID:35964836 thapsigargin increases expression ISO RGD:732479 6480464 Thapsigargin results in increased expression of ERO1A protein CTD PMID:35964836 thapsigargin increases expression ISO RGD:1317870 6480464 Thapsigargin results in increased expression of ERO1A protein CTD PMID:35964836 thifluzamide increases expression ISO RGD:1317870 6480464 thifluzamide results in increased expression of ERO1A mRNA CTD PMID:33512557 trametinib multiple interactions ISO RGD:1317870 6480464 [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ERO1A mRNA CTD PMID:36139627 trichostatin A increases expression ISO RGD:1317870 6480464 trichostatin A results in increased expression of ERO1A mRNA CTD PMID:24935251 trimellitic anhydride increases expression ISO RGD:732479 6480464 trimellitic anhydride results in increased expression of ERO1A mRNA CTD PMID:19042947 troglitazone multiple interactions ISO RGD:732479 6480464 [Troglitazone results in increased activity of PPARG protein] which results in increased expression of ERO1A mRNA CTD PMID:17452443 tunicamycin increases expression ISO RGD:732479 6480464 Tunicamycin results in increased expression of ERO1A mRNA CTD PMID:12752442 valproic acid increases expression ISO RGD:1317870 6480464 Valproic Acid results in increased expression of ERO1A mRNA CTD PMID:23179753 more ... valproic acid multiple interactions ISO RGD:1317870 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERO1A mRNA CTD PMID:27188386 valproic acid affects expression ISO RGD:1317870 6480464 Valproic Acid affects the expression of ERO1A mRNA CTD PMID:25979313 valproic acid decreases methylation ISO RGD:1317870 6480464 Valproic Acid results in decreased methylation of ERO1A gene CTD PMID:29154799 zoledronic acid increases expression ISO RGD:1317870 6480464 Zoledronic Acid results in increased expression of ERO1A mRNA CTD PMID:24714768 , PMID:25596134
